- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Femasys-Aktie steigt nach CE-Kennzeichnung für FemBloc zur dauerhaften Empfängnisverhütung | 2 | Investing.com Deutsch | ||
| Do | Femasys stock rises as FemBloc gets CE Mark for permanent birth control | 1 | Investing.com | ||
| FEMASYS Aktie jetzt für 0€ handeln | |||||
| Mi | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| Mi | Femasys Inc.: Femasys Announces Historic Milestone with European Approval of FemBloc, the First Non-Surgical Permanent Birth Control | 124 | GlobeNewswire (Europe) | ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive... ► Artikel lesen | |
| 17.06. | Femasys appoints Kelley Nicholas as chief commercial officer | 1 | Investing.com | ||
| 17.06. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 11.06. | The Analyst Verdict: Femasys In The Eyes Of 6 Experts | 2 | Benzinga.com | ||
| 11.06. | Femasys Inc.: Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed in its More than 8 Locations | 1 | GlobeNewswire (USA) | ||
| 02.06. | FEMASYS INC - 8-K, Current Report | - | SEC Filings | ||
| 30.05. | Femasys Announces $4.5 Mln Offering Through Public Sale And Private Placement Of Shares | 1 | RTTNews | ||
| 30.05. | Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M | 2 | Seeking Alpha | ||
| 30.05. | Femasys Inc.: Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million | 3 | GlobeNewswire (USA) | ||
| 29.05. | Femasys plans stock offering and private placement | 1 | Investing.com | ||
| 29.05. | Femasys announces public offering, concurrent private placement | 1 | Seeking Alpha | ||
| 29.05. | Femasys plant Aktienangebot und Privatplatzierung | 2 | Investing.com Deutsch | ||
| 29.05. | Femasys Inc.: Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 23.05. | Femasys droht Delisting von der NASDAQ | 1 | Investing.com Deutsch | ||
| 23.05. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Jones Trading cuts Femasys stock target to $6, maintains Buy | 1 | Investing.com | ||
| 09.05. | Analyst Expectations For Femasys' Future | 2 | Benzinga.com |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 459,00 | +0,71 % | Intuitive Surgical Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| UNITEDHEALTH | 263,95 | -0,02 % | Dividendenbekanntmachungen (24.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) COMPAGNIE DE L ODET SA FR0000062234 - 4,4 EUR DOM DEVELOPMENT SA PLDMDVL00012 7 PLN 1,6374 EUR ELBIT SYSTEMS LTD IL0010811243 0... ► Artikel lesen | |
| ROKU | 73,28 | -1,32 % | This 30-second fix made my Roku TV run like new again (and why it works) | ||
| ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| CENTENE | 45,970 | -0,35 % | Centene-Aktie läuft heute schlechter (46,0076 €) | Im Minus liegt aktuell der Anteilsschein von Centene . Die Aktie kostete zuletzt 53,62 US-Dollar. Ein Preisabschlag in Höhe von 43 Cent müssen derzeit die Aktionäre von Centene hinnehmen. Für das Papier... ► Artikel lesen | |
| VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| QUIDELORTHO | 24,200 | +0,83 % | Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now | ||
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| NANO-X IMAGING | 5,230 | -2,79 % | Nanox Imaging to Present at the Investor Summit Virtual on June 10, 2025 | PETACH TIKVA, ISRAEL / ACCESS Newswire / June 9, 2025 / Nanox Imaging announced that Ran Daniel, Chief Financial Officer, will be presenting at the Investor Summit Virtual taking place on June 10.About... ► Artikel lesen | |
| FULGENT GENETICS | 16,700 | 0,00 % | Fulgent genetics targets $310M core revenue in 2025 with strong growth in diagnostics and pathology | ||
| LANTHEUS | 69,56 | -0,09 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,940 | -8,70 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Commences Recruitment for [212Pb]VMT-a-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial | [212Pb]VMT-a-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 16,700 | -1,18 % | AMN Healthcare Services Inc: Celia Huber Joins AMN Healthcare Board of Directors | ||
| OMNICELL | 25,000 | -0,79 % | Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results | FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery... ► Artikel lesen |
FEMASYS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,66 % bei einem Aktienkurs von 0,977 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.